Why Biogen’s medication, aducanumab, should get studied through an important part of the Affordable Care Act, the Patient Centers Outcomes Research Institute.
Merrill Goozner
Merrill Goozner, a former editor of Modern Healthcare, publishes GoozNews on Substack, where this post originally appeared.
Posted inFeatured, Health Care, Political Animal
The All-Payer Pricing Alternative
Public option proponents face huge political hurdles; there is another way to achieve many of the same goals.
Posted inFeatured, Health Care, Political Animal
Biden’s Pivot on Drug Price Controls
The president abandons the long-held view that innovation requires high prices.
Posted inBooks, Featured, Health Care, Political Animal, Politics
Obamacare and Its Enemies
An insightful new history of the Affordable Care Act—and the fight to save it—points to a difficult road ahead for insuring Americans.
Posted inApril/May/June 2020, Health Care, Magazine
Why Are Patient Groups Silent on High Drug Prices?
Until advocates are willing to take on Big Pharma, reform efforts have no chance.
Posted inMagazine
Trial and Error
Are things about to change? The signs are certainly there. First, the Bush administration’s deeply-flawed Medicare drug benefit, which passed late last year after an unprecedented all-night session of arm-twisting, has proved unpopular with the public, and especially with seniors, largely because of the giveaways to pharmaceutical companies insisted upon by the GOP. Not only […]
Posted inMagazine
Drug Antics
Nowhere has this connection between horrific events and “regulatory creep”–the deliberately obfuscating phrase favored by conservative deregulators–been more apparent than in the evolution of the nation’s food and drug laws. Only after Upton Sinclair’s The Jungle alerted average Americans to the human butchery taking place inside meatpacking plants did Congress, in 1906, create an agency […]
